Last edition
News about "Cancer Drug Development"
Racura Oncology Advances RC220 to Higher Dose Level in Phase 1 CPACS Cancer Trial
Racura Oncology has received approval from the Safety Review Committee to escalate the dose of investigational cancer therapy RC220 in its phase 1 CPACS clinical trial following positive safety findings in advanced metastatic cancer patients.
Cancer Drug Development | 19/05/2026 | By News Bureau
GlycoNex Secures PMDA Nod for First-in-Human Trial of Cancer Drug GNX1021
Japan’s Pharmaceuticals and Medical Devices Agency approves Phase I clinical trial of GlycoNex’s novel antibody-drug conjugate targeting gastrointestinal cancers.
Cancer Drug Development | 16/04/2026 | By News Bureau | 124
Oncodesign Services Expands Collaboration with GIP ARRONAX to Advance Targeted Radiotherapy Research
Oncodesign Services strengthens partnership with GIP ARRONAX to secure access to rare radionuclides like astatine-211, supporting preclinical development of next-generation targeted radiotherapy treatments for cancer and other diseases.
Cancer Drug Development | 14/04/2026 | By News Bureau | 115
The collaboration between Boehringer Ingelheim and BioNTech will evaluate a dual immuno-oncology approach in extensive-stage small cell lung cancer, aiming to improve outcomes in a disease with limited treatment options.
Cancer Drug Development | 11/04/2026 | By News Bureau | 107
Breakthru Medicine Raises USD 60 Million Series A to Advance Cancer Drugs
Founded by biotech veterans Steve Potts, Mark Mulvihill and Brian Barnett, Breakthru Medicine has raised USD 60 million in Series A funding to advance its stealth oncology pipeline, including molecular glues, small molecules and novel ADC payloads.
Cancer Drug Development | 02/02/2026 | By News Bureau | 161
Cellectar Biosciences Partners with ITM to Secure Actinium-225 Supply for Cancer Drug Development
Cellectar Biosciences, Inc., a late-stage clinical biopharmaceutical company focused on cancer drug discovery and development, has entered into a supply agreement with ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech firm, for Actinium-225 (Ac-225).
Cancer Drug Development | 15/09/2025 | By Darshana | 249
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy